MX387806B - Inhibidores biciclicos con puente sustituidos de menina-mll y metodos de uso - Google Patents
Inhibidores biciclicos con puente sustituidos de menina-mll y metodos de usoInfo
- Publication number
- MX387806B MX387806B MX2018011092A MX2018011092A MX387806B MX 387806 B MX387806 B MX 387806B MX 2018011092 A MX2018011092 A MX 2018011092A MX 2018011092 A MX2018011092 A MX 2018011092A MX 387806 B MX387806 B MX 387806B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- menin
- mll
- bridged bicyclic
- bicyclic inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662309362P | 2016-03-16 | 2016-03-16 | |
| US201662431387P | 2016-12-07 | 2016-12-07 | |
| PCT/US2017/022535 WO2017161002A1 (en) | 2016-03-16 | 2017-03-15 | Bridged bicyclic inhibitors of menin-mll and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018011092A MX2018011092A (es) | 2018-11-22 |
| MX387806B true MX387806B (es) | 2025-03-19 |
Family
ID=59851929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018011092A MX387806B (es) | 2016-03-16 | 2017-03-15 | Inhibidores biciclicos con puente sustituidos de menina-mll y metodos de uso |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10752639B2 (enExample) |
| EP (1) | EP3429585B1 (enExample) |
| JP (1) | JP7000333B2 (enExample) |
| KR (1) | KR102419524B1 (enExample) |
| CN (1) | CN109640987B (enExample) |
| AU (1) | AU2017235462B2 (enExample) |
| BR (1) | BR112018068702A2 (enExample) |
| CA (1) | CA3015845A1 (enExample) |
| IL (1) | IL261625B (enExample) |
| MA (1) | MA43823A (enExample) |
| MX (1) | MX387806B (enExample) |
| MY (1) | MY199965A (enExample) |
| PH (1) | PH12018501955B1 (enExample) |
| SG (1) | SG11201807834WA (enExample) |
| TW (1) | TWI743096B (enExample) |
| WO (1) | WO2017161002A1 (enExample) |
| ZA (1) | ZA201805845B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016040330A1 (en) | 2014-09-09 | 2016-03-17 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| WO2016197027A1 (en) | 2015-06-04 | 2016-12-08 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| JP7000333B2 (ja) | 2016-03-16 | 2022-02-10 | クラ オンコロジー，インク． | メニン－ｍｌｌの架橋された二環式阻害剤及びその使用方法 |
| SG11201807982UA (en) | 2016-03-16 | 2018-10-30 | Kura Oncology Inc | Substituted inhibitors of menin-mll and methods of use |
| SG11201809714TA (en) | 2016-05-02 | 2018-11-29 | Univ Michigan Regents | Piperidines as menin inhibitors |
| KR102436430B1 (ko) | 2016-06-10 | 2022-08-24 | 비타이 파마슈티컬즈, 엘엘씨 | 메닌-mll 상호 작용의 억제제 |
| AU2017326487B2 (en) | 2016-09-14 | 2021-08-05 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| US10611778B2 (en) | 2016-09-14 | 2020-04-07 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-MLL interaction |
| BR112019012106A2 (pt) | 2016-12-15 | 2019-10-29 | Janssen Pharmaceutica Nv | inibidores de azepano de interação menin-mill |
| WO2018109088A1 (en) | 2016-12-15 | 2018-06-21 | Janssen Pharmaceutica Nv | Azepane inhibitors of menin-mll interaction |
| US11944627B2 (en) | 2017-03-24 | 2024-04-02 | Kura Oncology, Inc. | Methods for treating hematological malignancies and Ewing's sarcoma |
| EP3600313A4 (en) | 2017-03-31 | 2020-09-23 | The Regents of The University of Michigan | PIPERIDINES AS COVALENT MENINE INHIBITORS |
| WO2018226976A1 (en) | 2017-06-08 | 2018-12-13 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| WO2019060365A1 (en) * | 2017-09-20 | 2019-03-28 | Kura Oncology, Inc. | SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| CN110204552B (zh) * | 2018-02-28 | 2021-08-17 | 中国科学院上海药物研究所 | 一类噻吩并[3,2-d]嘧啶衍生物、其制备方法、药物组合物与用途 |
| WO2019189732A1 (ja) | 2018-03-30 | 2019-10-03 | 大日本住友製薬株式会社 | 光学活性な架橋型環状２級アミン誘導体 |
| CN113164443A (zh) * | 2018-09-26 | 2021-07-23 | 库拉肿瘤学公司 | 用多发性内分泌抑癌蛋白抑制剂治疗血液系统恶性肿瘤 |
| CN110964016B (zh) * | 2018-09-29 | 2021-05-28 | 南京药捷安康生物科技有限公司 | 氨基降茨烷衍生物及其制备方法与应用 |
| CA3116141C (en) | 2018-12-06 | 2023-09-05 | Daiichi Sankyo Company, Limited | Cycloalkane-1,3-diamine derivative |
| US11174263B2 (en) | 2018-12-31 | 2021-11-16 | Biomea Fusion, Inc. | Inhibitors of menin-MLL interaction |
| AU2019417833B2 (en) | 2018-12-31 | 2024-11-07 | Biomea Fusion, Inc. | Irreversible inhibitors of menin-MLL interaction |
| JP7465883B2 (ja) | 2019-02-15 | 2024-04-11 | ブリストル－マイヤーズ スクイブ カンパニー | ファルネソイドｘ受容体モジュレータとしての置換二環式化合物 |
| US12319676B2 (en) | 2019-02-15 | 2025-06-03 | Bristol-Myers Squibb Company | Substituted amide compounds useful as farnesoid X receptor modulators |
| EP3924329A2 (en) | 2019-02-15 | 2021-12-22 | Bristol-Myers Squibb Company | Substituted amide compounds useful as farnesoid x receptor modulators |
| IL293965A (en) | 2019-12-19 | 2022-08-01 | Janssen Pharmaceutica Nv | History of Spiro straight chain transformed |
| CN111297863B (zh) * | 2020-03-30 | 2021-06-25 | 四川大学华西医院 | menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用 |
| CN115698013A (zh) * | 2020-04-07 | 2023-02-03 | 赛达克斯制药股份有限公司 | Menin抑制剂和cyp3a4抑制剂的组合及其使用方法 |
| WO2022086986A1 (en) * | 2020-10-21 | 2022-04-28 | Kura Oncology, Inc. | Treatment of hematological malignancies with inhibitors of menin |
| BR112023023154A2 (pt) | 2021-05-08 | 2024-01-23 | Janssen Pharmaceutica Nv | Derivados espiro substituídos |
| WO2022237627A1 (en) | 2021-05-08 | 2022-11-17 | Janssen Pharmaceutica Nv | Substituted spiro derivatives |
| EP4337203A4 (en) | 2021-05-14 | 2025-04-09 | Syndax Pharmaceuticals, Inc. | INHIBITORS OF THE MENIN-MLL INTERACTION |
| CA3218479A1 (en) | 2021-06-01 | 2022-12-08 | Wei Cai | Substituted phenyl-1h-pyrrolo[2, 3-c]pyridine derivatives |
| US20250333421A1 (en) | 2021-06-03 | 2025-10-30 | Janssen Pharmaceutica Nv | Pyridazines or 1,2,4-triazines substituted by spirocyclic amines |
| CN117597348A (zh) | 2021-06-17 | 2024-02-23 | 詹森药业有限公司 | 用于治疗诸如癌症的疾病的(r)-n-乙基-5-氟-n-异丙基-2-((5-(2-(6-((2-甲氧基乙基)(甲基)氨基)-2-甲基己-3-基)-2,6-二氮杂螺[3.4]辛-6-基)-1,2,4-三嗪-6-基)氧基)苯甲酰胺苯磺酸盐 |
| CA3228627A1 (en) | 2021-08-11 | 2023-02-16 | Thomas Butler | Covalent inhibitors of menin-mll interaction for diabetes mellitus |
| EP4387972A1 (en) | 2021-08-20 | 2024-06-26 | Biomea Fusion, Inc. | Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer |
| IL316829A (en) * | 2022-05-09 | 2025-01-01 | Syndax Pharmaceuticals Inc | Menin-MLL inhibitors for cancer treatment |
| AU2023385514A1 (en) | 2022-11-24 | 2025-07-10 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer |
| WO2024155710A1 (en) | 2023-01-18 | 2024-07-25 | Biomea Fusion, Inc. | Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5863A (en) | 1848-10-17 | Matthias p | ||
| US510A (en) | 1837-12-07 | soeel | ||
| US949A (en) | 1838-09-27 | Improvement in roller cotton-gins for ginning long-staple and other kinds of cotton | ||
| US5861A (en) | 1848-10-17 | Locking umbrella and parasol | ||
| US1007727A (en) | 1908-02-17 | 1911-11-07 | Oscar F Onken | Auxiliary table-top. |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| DE4239169A1 (de) | 1992-11-21 | 1994-05-26 | Merck Patent Gmbh | Cyclobutan - Benzol - Derivate |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| FI973974A7 (fi) | 1995-04-20 | 1997-10-16 | Pfizer | Aryylisulfonyylihydroksaamihappojohdannaisia MMP- ja TNF-inhibiittorei na |
| DE69624081T2 (de) | 1995-12-20 | 2003-06-12 | Agouron Pharmaceuticals, Inc. | Matrix-metalloprotease Inhibitoren |
| JP3195756B2 (ja) | 1996-07-04 | 2001-08-06 | 公子 吉水 | 潤滑補助体 |
| HUP9903014A3 (en) | 1996-07-18 | 2000-08-28 | Pfizer | Phosphinate derivatives having matrix metalloprotease inhibitor effect and medicaments containing the same |
| JP3333870B2 (ja) | 1996-07-26 | 2002-10-15 | 国土交通省北陸地方整備局長 | 草刈機 |
| IL128189A0 (en) | 1996-08-23 | 1999-11-30 | Pfizer | Arylsulfonylamino hydroxamic acid derivatives |
| US5866562A (en) | 1996-10-25 | 1999-02-02 | Bayer Aktiengesellschaft | Ring-bridged bis-quinolines |
| ES2224277T3 (es) | 1997-01-06 | 2005-03-01 | Pfizer Inc. | Derivados de sulfonas ciclicas. |
| PT977733E (pt) | 1997-02-03 | 2003-12-31 | Pfizer Prod Inc | Derivados de acido arilsulfonilamino-hidroxamico |
| JP2000507975A (ja) | 1997-02-07 | 2000-06-27 | ファイザー・インク | Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用 |
| IL131123A0 (en) | 1997-02-11 | 2001-01-28 | Pfizer | Arylsulfonyl hydroxamic acid derivatives |
| JPH10330377A (ja) | 1997-06-02 | 1998-12-15 | Kyowa Hakko Kogyo Co Ltd | ピペリジン誘導体 |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| US6479487B1 (en) | 1998-02-26 | 2002-11-12 | Aventis Pharmaceuticals Inc. | 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| DE60227794D1 (de) | 2001-04-26 | 2008-09-04 | Eisai R&D Man Co Ltd | Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon |
| JP2005503345A (ja) | 2001-04-30 | 2005-02-03 | バイエル・コーポレーシヨン | 新規な４−アミノ−５，６−置換チオフェノ［２，３−ｄ］ピリミジン |
| AU2002336462A1 (en) | 2001-09-06 | 2003-03-24 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
| AU2003255482A1 (en) | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4 amino-quinazolines as anti cancer agents |
| AU2003258662A1 (en) | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4-amino-quinazolines as anti cancer agents |
| US7612078B2 (en) | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| US20050222175A1 (en) | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| AU2004227913B2 (en) | 2003-03-31 | 2010-12-02 | Trovis Pharmaceuticals, Llc | New piperidinylamino-thieno(2,3-d) pyrimidine compounds |
| EP1663962A4 (en) | 2003-08-22 | 2007-08-22 | Dendreon Corp | COMPOSITIONS AND METHODS FOR TREATING A DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION |
| US20050123906A1 (en) | 2003-11-06 | 2005-06-09 | Rana Tariq M. | Protein modulation |
| US20060025406A1 (en) | 2004-07-06 | 2006-02-02 | Angion Biomedica Corporation | Modulators of hepatocyte growth factor/c- Met activity |
| ATE530519T1 (de) | 2005-06-03 | 2011-11-15 | Abbott Lab | Cyclobutylaminderivate |
| US20060281771A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators |
| US20060281769A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators |
| AU2006286441A1 (en) | 2005-09-02 | 2007-03-08 | Janssen R&D Ireland | Benzodiazepines as HCV inhibitors |
| EP1926798B1 (de) | 2005-09-19 | 2009-09-30 | Merck Patent GmbH | Cyclobutan- und spiro[3.3]heptanverbindungen |
| FR2891829A1 (fr) | 2005-10-12 | 2007-04-13 | Sanofi Aventis Sa | Derives de la 4-amino-quinazoline, leur preparation et leur application en therapeutique |
| ES2378473T3 (es) | 2005-12-21 | 2012-04-12 | Abbott Laboratories | Compuestos antivirales |
| US8633201B2 (en) | 2006-04-07 | 2014-01-21 | Boehringer Ingelheim International Gmbh | Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions |
| EP1903044A1 (en) | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
| WO2008070303A2 (en) | 2006-10-19 | 2008-06-12 | The University Of Chicago | Therapeutics to inhibit mll-menin interaction for treating leukemia |
| EP1947103A1 (en) | 2007-01-22 | 2008-07-23 | 4Sc Ag | Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments |
| WO2008099019A1 (en) | 2007-02-16 | 2008-08-21 | Tibotec Pharmaceuticals Ltd. | 6-hydroxy-dibenzodiazepinones useful as hepatitis c virus inhibitors |
| FR2913017A1 (fr) | 2007-02-23 | 2008-08-29 | Cerep Sa | Derives de piperidine et piperazine comme agents anti-neoplasiques ou inhibiteurs de proliferation cellulaire |
| EP2150527B1 (en) | 2007-03-19 | 2011-01-19 | Council of Scientific & Industrial Research | Anthranilic acid derivative as anticancer agent and a process for the preparation thereof |
| WO2008135232A1 (en) | 2007-05-02 | 2008-11-13 | Riccardo Cortese | Use and compositions of purine derivatives for the treatment of proliferative disorders |
| CA2687187A1 (en) | 2007-05-25 | 2008-12-18 | Burnham Institute For Medical Research | Inhibitors of thapsigargin-induced cell death |
| WO2009017838A2 (en) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| US20110124649A1 (en) | 2007-11-09 | 2011-05-26 | The Johns Hopkins University | Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders |
| AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| KR20110018380A (ko) | 2008-05-22 | 2011-02-23 | 알러간, 인코포레이티드 | Ｃｘｃｒ4 수용체에서 활성을 갖는 이환식 화합물 |
| DE102008027574A1 (de) | 2008-06-10 | 2009-12-17 | Merck Patent Gmbh | Neue Pyrrolidinderivate als MetAP-2 Inhibitoren |
| EP2328871B1 (en) | 2008-08-25 | 2020-04-01 | Novartis AG | Hedgehog pathway modulators |
| MX2011002263A (es) | 2008-09-10 | 2011-05-23 | Kalypsys Inc | Aminopirimidinas como inhibidores de receptores de histamina para el tratamiento de enfermedades. |
| TW201105674A (en) | 2009-07-08 | 2011-02-16 | Leo Pharma As | Novel JAK receptor and protein tyrosine kinase inhibitors and pharmaceutical use thereof |
| US8742100B2 (en) | 2009-07-30 | 2014-06-03 | National University Of Singapore | Small molecule inhibitors of isoprenylcysteine carboxyl methyltransferase with potential anticancer activity |
| EP2473054B1 (en) | 2009-09-04 | 2017-06-14 | The Regents of the University of Michigan | Compositions and methods for treatment of leukemia |
| WO2011101069A2 (en) | 2010-02-22 | 2011-08-25 | Merck Patent Gmbh | Hetarylaminonaphthyridines |
| JP5749341B2 (ja) | 2010-08-20 | 2015-07-15 | ハチソン メディファーマ リミテッド | ピロロピリミジン化合物およびその使用 |
| WO2013019966A1 (en) * | 2011-08-04 | 2013-02-07 | Allergan, Inc. | Aromatic bycyclic derivatives as cxcr4 receptor modulators |
| GB201114212D0 (en) | 2011-08-18 | 2011-10-05 | Ucb Pharma Sa | Therapeutic agents |
| AR090037A1 (es) | 2011-11-15 | 2014-10-15 | Xention Ltd | Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio |
| CN103833759A (zh) * | 2012-11-23 | 2014-06-04 | 华东理工大学 | 作为blk、flt3抑制剂的蝶啶酮衍生物及其应用 |
| EP2968342B1 (en) | 2013-03-13 | 2018-10-03 | The Regents of the University of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
| US9771327B2 (en) | 2013-03-13 | 2017-09-26 | Flatley Discovery Lab, Llc | Compounds and methods for the treatment of cystic fibrosis |
| US9212180B2 (en) * | 2013-06-12 | 2015-12-15 | The Regents Of The University Of Michigan | Menin-MLL inhibitors and methods of use thereof |
| DK3126352T3 (en) * | 2014-04-04 | 2019-01-21 | Syros Pharmaceuticals Inc | CYCLINE INDEPENDENT KINASE 7 INHIBITORS (CDK7) |
| US20170119769A1 (en) * | 2014-06-10 | 2017-05-04 | The Trustees Of The University Of Pennsylvania | Scaffolds for inhibitors of menin-mll interactions |
| WO2016040330A1 (en) | 2014-09-09 | 2016-03-17 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| WO2016197027A1 (en) | 2015-06-04 | 2016-12-08 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| AU2016378579A1 (en) | 2015-12-22 | 2018-06-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-MLL interaction |
| CA3012649A1 (en) | 2016-01-26 | 2017-08-03 | Memorial Sloan-Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression in npm1 mutant leukemia |
| JP7000333B2 (ja) | 2016-03-16 | 2022-02-10 | クラ オンコロジー，インク． | メニン－ｍｌｌの架橋された二環式阻害剤及びその使用方法 |
| SG11201807982UA (en) | 2016-03-16 | 2018-10-30 | Kura Oncology Inc | Substituted inhibitors of menin-mll and methods of use |
| SG11201809714TA (en) | 2016-05-02 | 2018-11-29 | Univ Michigan Regents | Piperidines as menin inhibitors |
| WO2017207387A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
| KR102436430B1 (ko) | 2016-06-10 | 2022-08-24 | 비타이 파마슈티컬즈, 엘엘씨 | 메닌-mll 상호 작용의 억제제 |
| WO2018024602A1 (en) | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
| US10611778B2 (en) | 2016-09-14 | 2020-04-07 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-MLL interaction |
| TWI738864B (zh) | 2016-09-14 | 2021-09-11 | 比利時商健生藥品公司 | Ｍｅｎｉｎ-ｍｌｌ相互作用之螺二環抑制劑 |
| IL265028B (en) | 2016-09-16 | 2022-09-01 | Vitae Pharmaceuticals Llc | Inhibitors of the menin-mil interaction |
-
2017
- 2017-03-15 JP JP2018544323A patent/JP7000333B2/ja active Active
- 2017-03-15 MX MX2018011092A patent/MX387806B/es unknown
- 2017-03-15 CA CA3015845A patent/CA3015845A1/en active Pending
- 2017-03-15 MA MA043823A patent/MA43823A/fr unknown
- 2017-03-15 WO PCT/US2017/022535 patent/WO2017161002A1/en not_active Ceased
- 2017-03-15 BR BR112018068702A patent/BR112018068702A2/pt not_active Application Discontinuation
- 2017-03-15 PH PH1/2018/501955A patent/PH12018501955B1/en unknown
- 2017-03-15 US US16/082,645 patent/US10752639B2/en active Active
- 2017-03-15 SG SG11201807834WA patent/SG11201807834WA/en unknown
- 2017-03-15 KR KR1020187029700A patent/KR102419524B1/ko active Active
- 2017-03-15 MY MYPI2018001516A patent/MY199965A/en unknown
- 2017-03-15 TW TW106108619A patent/TWI743096B/zh active
- 2017-03-15 EP EP17767444.7A patent/EP3429585B1/en active Active
- 2017-03-15 CN CN201780030449.4A patent/CN109640987B/zh active Active
- 2017-03-15 AU AU2017235462A patent/AU2017235462B2/en active Active
-
2018
- 2018-08-30 ZA ZA2018/05845A patent/ZA201805845B/en unknown
- 2018-09-05 IL IL261625A patent/IL261625B/en unknown
-
2020
- 2020-07-13 US US16/927,844 patent/US11555041B2/en active Active
-
2025
- 2025-01-10 US US19/017,093 patent/US20250340566A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210107917A1 (en) | 2021-04-15 |
| AU2017235462B2 (en) | 2021-07-01 |
| CN109640987A (zh) | 2019-04-16 |
| SG11201807834WA (en) | 2018-10-30 |
| JP7000333B2 (ja) | 2022-02-10 |
| WO2017161002A1 (en) | 2017-09-21 |
| MA43823A (fr) | 2018-11-28 |
| EP3429585B1 (en) | 2021-11-24 |
| CA3015845A1 (en) | 2017-09-21 |
| TWI743096B (zh) | 2021-10-21 |
| US20250340566A1 (en) | 2025-11-06 |
| MY199965A (en) | 2023-11-30 |
| EP3429585A4 (en) | 2019-10-09 |
| US11555041B2 (en) | 2023-01-17 |
| BR112018068702A2 (pt) | 2019-01-15 |
| HK1258821A1 (en) | 2019-11-22 |
| ZA201805845B (en) | 2023-03-29 |
| KR102419524B1 (ko) | 2022-07-08 |
| US10752639B2 (en) | 2020-08-25 |
| IL261625B (en) | 2021-08-31 |
| KR20180127406A (ko) | 2018-11-28 |
| IL261625A (en) | 2018-10-31 |
| AU2017235462A1 (en) | 2018-09-27 |
| US20190092783A1 (en) | 2019-03-28 |
| PH12018501955A1 (en) | 2019-06-17 |
| PH12018501955B1 (en) | 2024-01-24 |
| TW201742870A (zh) | 2017-12-16 |
| JP2019508426A (ja) | 2019-03-28 |
| MX2018011092A (es) | 2018-11-22 |
| EP3429585A1 (en) | 2019-01-23 |
| CN109640987B (zh) | 2022-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202310395B (en) | Substituted inhibitors of menin-mll and methods of use | |
| PH12018501955A1 (en) | Bridged bicyclic inhibitors of menin-mll and methods of use | |
| MY186712A (en) | Methods and compositions for inhibiting the interaction of menin with mll proteinss | |
| HK1246593A1 (zh) | 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物 | |
| PH12021551439A1 (en) | Irreversible inhibitors of menin-mll interaction | |
| MX2015011576A (es) | Composiciones que comprenden compuestos de tienopirimidina y tienopiridina y metodos para usar los mismos. | |
| SG10201809428UA (en) | Insulin receptor partial agonists | |
| ZA201708000B (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
| PH12018500711A1 (en) | Anti-pd1 antibodies and methods of use | |
| MX2021010482A (es) | Compuestos y metodos para la degradacion mejorada de proteinas especificas. | |
| PH12017501481A1 (en) | Bicyclic heterocycles as fgfr inhibitors | |
| EP4230627A3 (en) | Inhibitors of the menin-mll interaction | |
| TR201909887T4 (tr) | ERK inhibitörleri olarak tieno[2,3-c]pirol-4-on türevleri. | |
| SG10201907582WA (en) | Bicyclic heterocycles as fgfr4 inhibitors | |
| MX2020012893A (es) | Formulaciones de proteinas. | |
| MX370897B (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades, | |
| MX2018004829A (es) | Métodos para medir la actividad de factor d y la potencia de inhibidores de factor d. | |
| EP3778644A3 (en) | Fgfr-tacc fusion proteins and methods thereof | |
| MX2018014034A (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades. | |
| EP4371613A3 (en) | Compounds for use in the treatment of ocular pain | |
| EA201892082A1 (ru) | Мостиковые бициклические ингибиторы менин-mll и способы применения | |
| EA201892083A1 (ru) | Замещенные ингибиторы менина-mll и способы применения |